Применение доксициклина у детей и подростков


Е.А. Ушкалова

Применение доксициклина
у детей и подростков
Использование тетрациклинов, в частности доксициклина, у детей младшего возраста длительное время было запрещено из-за потенциальной опасности поражения зубной эмали. В последние годы оценка соотношения польза/риск для тетрациклинов в педиатрии при некоторых инфекциях была пересмотрена, и показания к применению этих антибиотиков, прежде всего доксициклина, у детей были существенно расширены. Это объясняется тем, что при ряде инфекций тетрациклины являются самыми активными антибиотиками, а потенциальные побочные эффекты альтернативных препаратов, рекомендовавшихся в качестве средств выбора детям младшего возраста, значительно серьезнее, чем косметические дефекты со стороны зубов, вызываемые тетрациклинами. Рассматривается применение доксициклина у детей при инфекциях дыхательных путей, хламидиозе, риккетсиозах и орнитозах, болезни Лайма, сибирской язве и некоторых других инфекциях. При многих заболеваниях доксициклин выступает в качестве препарата первого выбора.

Литература






  1. Abramson JS, Givner LB. Should tetracycline be contraindicated for therapy of presumed rocky mountain spotted fever in children less than 9 years of age? Pediatrics 1990;86:123–24.


  2. Cunha BA. Community-Acquired Pneumonia. Infect Med 2003;20:27–30.


  3. Shetty AK. Tetracyclines in pediatrics revisited. Clin Pediatr 2002;41:203–09.


  4. Burnham TH, ed. Drug Facts and Comparisons. 2003. St. Louis: Facts and Comparisons, Inc.:348–348a.


  5. Singh J, Arrieta AC. Of bugs and drugs. A guide through the labyrinth of antimicrobial therapy for respiratory tract infections. Postgraduate Medicine 1999:106 (6).


  6. Peipert JF. Genital Chlamydial infections. NEJM 2003;349(25):2424–30.


  7. Cromwell PF, Risser WL, Risser JM. Prevalence and incidence of pelvic inflammatory disease in incarcerated adolescents. Sex Transm Dis 2002; 29: 391–96.


  8. Прилепская В.Н., Абуд И.Ю. Хламидийная инфекция в акушерстве и гинекологии // РМЖ. 1998. № 5.


  9. Chuen-Yen Lau, Azhar K. Qureshi. Azithromycin Versus Doxycycline for Genital Chlamydial Infections:A Meta-Analysis of Randomized Clinical Trials. Sexually Transmitted Diseases 2002;29: 497–502.


  10. Compliance a Key Consideration in Treating Concurrent Gonorrhoea and Chlamydia Infection. Drug Ther Perspect 2001;17(9):4–9.


  11. Carne C. Recent advances: sexually transmitted infections. BMJ 1998;317:129–32.


  12. Lassus A. Comparative studies of azithromycin in skin and soft-tissue infections and sexually transmitted infections by Neisseria and Chlamydia species. J Antimicrob Chemother 1990;25(suppl. A):115–21.


  13. Никонов А.П., Сехин С.В., Анкирская А.С. Инфекции в акушерстве и гинекологии // Практическое руководство по антиинфекционной химиотерапии / под ред. Л.С. Страчунского, Ю.Б. Белоусова, С.Н. Козлова. М., 2002. С. 252–256.


  14. Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines, MMWR 2002;51(RR-6):48–52.


  15. Buck ML. Doxycycline for Pediatric Infections. Pediatr Pharm 2003;9(10).


  16. Dalton MJ, Clarke MJ, Holman RC, et al. National surveillance for Rocky Mountain spotted fever: 1981-1992: epidemiologic summary and evaluation of risk factors for fatal outcome. Am J Trop Med Hyg 1995;52:405–13.


  17. Kirkland KB, Wilkinson WE, Sexton DJ. Therapeutic delay and mortality in cases of Rocky Mountain spotted fever. Clin Infect Dis 1995;20: 1118–21.


  18. Purvis JJ, Edwards MS. Doxycycline use for rickettsial disease in pediatric patients. Pediatr Infect Dis J 2000;19:871–4.


  19. American Academy of Pediatrics. Lyme disease. In: Pickering LK, ed. 2003 Red Book: Report of the Committee on Infectious Diseases. 26[th] ed. Elk Grove Village, IL: American Academy of Pediatrics 2003:407–11.


  20. Shapiro ED, Gerber MA. Lyme disease: fact versus fiction. Pediatr Ann 2003;31:170–77.


  21. Wormser GP, Nadelman RB, Dattwyler RJ, et al. Practice guidelines for the treatment of Lyme disease. Clin Infect Dis 2000;31(suppl. 1):S1–14.


  22. Dotevall L, Hagberg L. Successful oral doxycycline treatment of Lyme disease-associated facial palsy and meningitis. Clin Infect Dis 1999; 28(3):569–74.


  23. Karlsson-M, Hammers-Berggren-S, Lindquist-L, et al. Comparison of intravenous penicillin G and oral doxycycline for treatment of Lyme neuroborreliosis. Neurology 1994;44(7):1203–7.


  24. Nadelman RB, Nowakowski J, Fish D, et al. Prophylaxis with Single-Dose Doxycycline for the Prevention of Lyme Disease after an Ixodes scapularis Tick Bite. N Engl J Med 2001;345(2): 79–84.


  25. Anon. Update: investigation of anthrax associated with intentional exposure and interim public health guidelines, October 2001. MMWR 2001;50:889–97.


  26. Anon. Update: interim recommendations for antimicrobial prophylaxis for children and breastfeeding mothers and treatment of children with anthrax. MMWR 2001;50:1014–6.


  27. Benavides S, Nahata MC. Anthrax: safe treatment for children. Ann Pharmacother 2002; 36:334–37.


  28. Taylor MJ, Makunde WH, McGarry HF, et al. Macrofilaricidal activity after doxycycline treatment of Wuchereria bancrofti: a double-blind, randomised placebo-controlled trial. Lancet 2005;365(9477):2116–21.


  29. Lochary ME, Lockhart PB, Williams WT. Doxycycline and staining of permanent teeth. Pediatr Infect Dis J 1998;17:429–31.


  30. Anon. How to prepare emergency dosages of doxycycline at home for infants and children. Food and Drug Administration Center for Drug Evaluation and Research. Available at www.fda.gov/cder/drug/infopage/penG_doxy /doxycyclinePeds.htm (accessed 9/30/03).


  31. Yu LX, Nguyenpho A, Roberts R, et al. Palatability evaluations of doxycycline solid dosage tablets ground and mixed in food or drinks. Food and Drug Administration Center for Drug Evaluation and Research. Available at www.fda.gov/ cder/drug/infopage/penG_doxy/doxy_food.htm (accessed 9/30/03).


  32. Brower JF, Moore TW, Reepmeyer JC, et al. Stability and dose uniformity evaluations of doxycycline solid dosage tablets ground and mixed in food or drinks. Food and Drug Administration Center for Drug Evaluation and Research. Available at www.fda.gov/cder/drug/infopage/ penG_doxy /stability_tables.htm (accessed 9/30/03).





Бионика Медиа